欧美日韩亚洲一区二区三区四区 ,91尤物视频盛宴,国产综合色产在线观看,国产欧美久久久精品影院,国内精品伊人久久久影视,欧美成人精品免费播放,国产麻豆精品一区二区三区v视界

Stock Code

688016.SH

Shanghai, China - Castor? Branched Aortic Stent-Graft System ("Castor?"), in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd ("MicroPort?"), recently obtained the regulatory approval from China Food and Drug Administration ("CFDA"). It is the fourth device of MicroPort? that gained the CFDA approval through the CFDA Green Path for innovative medical devices.

 

Castor? is the endovascular device used to preserve the branch artery while repair the thoracic aorta. Its unique "unibody design" could accommodate diverse arch anatomy. It is also the world's first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery and 20mm distal to the left carotid artery. Castor? adopts the "unibody design", which is sewing the main body and branch stent together to make it possible to deploy and release at the same time. This design innovatively accomplishes deployment and positioning of the unibody branched stent graft, achieving low endoleak rate and better branch artery patency, which reduces the operative trauma and improves safety during the procedure. Castor? also employs several unique designs, such as kink-free outer sheath design, soft sheath design with excellent arch crossability, and branch stent sheath.

 

Aortic dilation diseases, in particular aortic dissection, are now commonly seen in China with the increasing incidence of atherosclerosis. Aortic dilation diseases are associated with high disability and death rates as they often lead to severe complications such as limb ischemia, visceral ischemia, and paraplegia. It is the emergence of the endovascular repair by stent graft endovascology that largely reduces the operative trauma. Though endovascular repair has become the main method to treat aortic dilation diseases, thoracic aortic dissection involving aortic arch branch artery, such as left subclavian artery, is still the relative contraindication of endovascular repair due to lack of suitable endovascular prosthesis. The launch of Castor? marks a significant step forward in using endovascular repair to treat aortic arch, making breakthroughs in a key area clinicians have spent many years to research and explore.

宽甸| 富宁县| 辽中县| 班玛县| 清涧县| 垫江县| 蒙山县| 尼勒克县| 甘德县| 新建县| 汉源县| 平果县| 界首市| 远安县| 六枝特区| 新疆| 攀枝花市| 洱源县| 岳普湖县| 榆社县| 水富县| 陈巴尔虎旗| 洛隆县| 西青区| 深水埗区| 临颍县| 云霄县| 平泉县| 洪湖市| 凤山县| 江山市| 南阳市| 耒阳市| 景谷| 什邡市| 雷波县| 大竹县| 新营市| 邹城市| 宜阳县| 宣恩县|